Lipitor Case Proves Strength Of Molecular Patents
India-based generic drug maker Ranbaxy Laboratories took the unusual step of seeking to invalidate Lipitor’s molecular compound patent, the very heart of a drug’s intellectual property.
The daring attack, an attempt to break into Lipitor’s wild financial success as the world’s top-selling drug, has so far failed. That may bring a...
To view the full article, register now.